As governments and advocacy groups push for price controls to make essential medications more accessible, the industry’s top executives are raking in millions, fueling controversy and highlighting stark disparities. For example, J&J, after paying Duato $13.1 million in his first year as CEO, the pharma giant more than doubled his…